Efficacy and Tolerance of JAK Inhibitors in ATU for Atopic Dermatitis

Effectiveness and Safety of JAK Inhibitors for the Treatment of Moderate-to-severe Atopic Dermatitis in a Real-life French Multicenter Adult Cohort

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04761978

Acronym

JAKIGREAT

Enrollment

Registered

2021-02-21

Start date

2021-09-01

Completion date

2022-09-01

Last updated

2026-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dermatitis, Atopic

Keywords

Effectiveness, Safety, JAK inhibitors, Atopic dermatitis, Adults

Brief summary

The aim is to assess effectiveness (EASI, SCORAD, IGA, DLQI, pruritus, sleep loss) and safety (clinical and biological adverse events) of JAK inhibitors in adults with moderate-to-severe atopic dermatitis in a real-life French multicenter retrospective cohort

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Adults * moderate to severe atopic dermatitis * treated by JAK inhibitors between december 2020 and september 2021 * inefficiency, loss of efficiency or contra-indication of previous systemic agent, DUPILUMAB or phototherapy * ineligibility to French ongoing clinical trials

Exclusion criteria

* Children * mild atopic dermatitis * eligibility to CICLOSPORINE, METHOTREXATE, DUPILUMAB, phototherapy * eligibility to French ongoing clinical trials * patients' opposition for the use of their records * follow up \<3 months

Design outcomes

Primary

Measure	Time frame
reduction in Eczema Area and Severity Index (EASI)	At 3 months

Secondary

Measure	Time frame
SCORing Atopic Dermatitis (SCORAD)	at baseline and at 3 months
Investigator's Global Assessment (IGA)	at baseline and at 3 months
Dermatology Life Quality Index (DLQI)	at baseline and at 3 months
patient-reported pruritus score from 0 to 10	at baseline and at 3 months
patient-reported sleep loss from 0 to 10	at baseline and at 3 months
Adverse effects (biological and clinical)	at baseline and at 3 month

Countries

France

Contacts

PRINCIPAL_INVESTIGATORDelphine Staumont-Salle, MD,PhD

University Hospital, Lille

Outcome results